As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
9 Analysts have issued a BioAtla Inc forecast:
9 Analysts have issued a BioAtla Inc forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | 11 11 |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -73 -73 |
43%
43%
|
|
| EBIT (Operating Income) EBIT | -74 -74 |
43%
43%
|
|
| Net Profit | -70 -70 |
43%
43%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Jay Short |
| Employees | 61 |
| Founded | 2007 |
| Website | www.bioatla.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


